Filing Flows › Foghorn Therapeutics (FHTX) › Q4 2025
Foghorn Therapeutics (FHTX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 11, 2026
Foghorn Therapeutics (FHTX) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), +224% from a year earlier and +13% from the quarter before. Operating margin was -258.2%, net loss $21.7M (234.3% of revenue).
Foghorn Therapeutics, Q4 2025: revenue $9.2M (+224% year over year), operating margin -258.2%, net loss $21.7M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | +13% | +224% |
| Operating profit | −$23.9M | — | — |
| Net earnings | −$21.7M | — | — |
| Operating cash flow | −$22.3M | — | — |
What changed
Revenue was $9.2M in Q4 2025, up 224% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $23.9M, an operating margin of -258.2%. Total costs grew 23% against revenue growth of 224%. The quarter ended with a net loss of $21.7M, wider than the previous quarter's $15.8M loss.
Operating cash flow was −$22.3M. Non-cash charges added back $802K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $3.6M.
Questions
What was Foghorn Therapeutics' revenue in the fourth quarter 2025?
Foghorn Therapeutics (FHTX) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), +224% from a year earlier and +13% from the quarter before.
Was Foghorn Therapeutics profitable in the fourth quarter 2025?
Operating loss was $23.9M (-258.2% of revenue) and net loss $21.7M.